These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 37395664)

  • 1. Broadly Effective ACE2 Decoy Proteins Protect Mice from Lethal SARS-CoV-2 Infection.
    Lu M; Yao W; Li Y; Ma D; Zhang Z; Wang H; Tang X; Wang Y; Li C; Cheng D; Lin H; Yin Y; Zhao J; Zhong G
    Microbiol Spectr; 2023 Aug; 11(4):e0110023. PubMed ID: 37395664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.
    Ferrari M; Mekkaoui L; Ilca FT; Akbar Z; Bughda R; Lamb K; Ward K; Parekh F; Karattil R; Allen C; Wu P; Baldan V; Mattiuzzo G; Bentley EM; Takeuchi Y; Sillibourne J; Datta P; Kinna A; Pule M; Onuoha SC
    J Virol; 2021 Sep; 95(19):e0068521. PubMed ID: 34287040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An inhaled ACE2 decoy confers protection against SARS-CoV-2 infection in preclinical models.
    Urano E; Itoh Y; Suzuki T; Sasaki T; Kishikawa JI; Akamatsu K; Higuchi Y; Sakai Y; Okamura T; Mitoma S; Sugihara F; Takada A; Kimura M; Nakao S; Hirose M; Sasaki T; Koketsu R; Tsuji S; Yanagida S; Shioda T; Hara E; Matoba S; Matsuura Y; Kanda Y; Arase H; Okada M; Takagi J; Kato T; Hoshino A; Yasutomi Y; Saito A; Okamoto T
    Sci Transl Med; 2023 Aug; 15(711):eadi2623. PubMed ID: 37647387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 and Three Related Coronaviruses Utilize Multiple ACE2 Orthologs and Are Potently Blocked by an Improved ACE2-Ig.
    Li Y; Wang H; Tang X; Fang S; Ma D; Du C; Wang Y; Pan H; Yao W; Zhang R; Zou X; Zheng J; Xu L; Farzan M; Zhong G
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32847856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
    Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
    mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses.
    Sims JJ; Lian S; Meggersee RL; Kasimsetty A; Wilson JM
    PLoS One; 2022; 17(8):e0271359. PubMed ID: 36006993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo.
    Havranek B; Lindsey GW; Higuchi Y; Itoh Y; Suzuki T; Okamoto T; Hoshino A; Procko E; Islam SM
    Commun Biol; 2023 May; 6(1):513. PubMed ID: 37173421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo.
    Ikemura N; Taminishi S; Inaba T; Arimori T; Motooka D; Katoh K; Kirita Y; Higuchi Y; Li S; Suzuki T; Itoh Y; Ozaki Y; Nakamura S; Matoba S; Standley DM; Okamoto T; Takagi J; Hoshino A
    Sci Transl Med; 2022 Jun; 14(650):eabn7737. PubMed ID: 35471044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS-CoV-2.
    Zhang L; Narayanan KK; Cooper L; Chan KK; Skeeters SS; Devlin CA; Aguhob A; Shirley K; Rong L; Rehman J; Malik AB; Procko E
    EMBO Mol Med; 2022 Nov; 14(11):e16109. PubMed ID: 36094679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness.
    Sui J; Deming M; Rockx B; Liddington RC; Zhu QK; Baric RS; Marasco WA
    J Virol; 2014 Dec; 88(23):13769-80. PubMed ID: 25231316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multivalent IgM scaffold enhances the therapeutic potential of variant-agnostic ACE2 decoys against SARS-CoV-2.
    Verstraete MM; Heinkel F; Li J; Cao S; Tran A; Halverson EC; Gene R; Stangle E; Silva-Moreno B; Arrafi S; Bavananthasivam J; Fung M; Eji-Lasisi M; Masterman S; Xanthoudakis S; Dixit S; Babcook J; Clavette B; Fogg M; Escobar-Cabrera E
    MAbs; 2023; 15(1):2212415. PubMed ID: 37229608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational design of AAVrh10-vectored ACE2 functional domain to broadly block the cell entry of SARS-CoV-2 variants.
    Li M; Chen J; Liu Y; Zhao J; Li Y; Hu Y; Chen YQ; Sun L; Shu Y; Feng F; Sun C
    Antiviral Res; 2022 Sep; 205():105383. PubMed ID: 35917969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses.
    Lim HT; Kok BH; Lim CP; Abdul Majeed AB; Leow CY; Leow CH
    Biomed Eng Adv; 2022 Dec; 4():100054. PubMed ID: 36158162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides.
    Llewellyn GN; Chen HY; Rogers GL; Huang X; Sell PJ; Henley JE; Cannon PM
    J Virol; 2023 Aug; 97(8):e0068423. PubMed ID: 37555663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering ACE2 decoy receptors to combat viral escapability.
    Arimori T; Ikemura N; Okamoto T; Takagi J; Standley DM; Hoshino A
    Trends Pharmacol Sci; 2022 Oct; 43(10):838-851. PubMed ID: 35902282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivo.
    Torchia JA; Tavares AH; Carstensen LS; Chen DY; Huang J; Xiao T; Mukherjee S; Reeves PM; Tu H; Sluder AE; Chen B; Kotton DN; Bowen RA; Saeed M; Poznansky MC; Freeman GJ
    Sci Adv; 2022 Dec; 8(49):eabq6527. PubMed ID: 36475798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble Angiotensin-Converting Enzyme 2 Protein Improves Survival and Lowers Viral Titers in Lethal Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Type 2 Infection with the Delta Variant.
    Cianfarini C; Hassler L; Wysocki J; Hassan A; Nicolaescu V; Elli D; Gula H; Ibrahim AM; Randall G; Henkin J; Batlle D
    Cells; 2024 Jan; 13(3):. PubMed ID: 38334597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACE2 decoy receptor generated by high-throughput saturation mutagenesis efficiently neutralizes SARS-CoV-2 and its prevalent variants.
    Wang B; Zhao J; Liu S; Feng J; Luo Y; He X; Wang Y; Ge F; Wang J; Ye B; Huang W; Bo X; Wang Y; Xi JJ
    Emerg Microbes Infect; 2022 Dec; 11(1):1488-1499. PubMed ID: 35587428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Soluble ACE2 Protein Provides Lung and Kidney Protection in Mice Susceptible to Lethal SARS-CoV-2 Infection.
    Hassler L; Wysocki J; Gelarden I; Sharma I; Tomatsidou A; Ye M; Gula H; Nicoleascu V; Randall G; Pshenychnyi S; Khurram N; Kanwar Y; Missiakas D; Henkin J; Yeldandi A; Batlle D
    J Am Soc Nephrol; 2022 Jul; 33(7):1293-1307. PubMed ID: 35236774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.